Merck-related articles on finasteride for BPH

This bibliography consists of medical literature on finasteride for benign prostatic hyperplasia (BPH) in which Merck played a direct or indirect role. An example of an indirect role is when external physicians hired by Merck as consultants wrote articles about finasteride for hair loss.

Researchers profiled in The Partnership appear in bold. Authors in italics are Merck researchers. RS Rittmaster was at Dalhousie University through approximately 2005, then moved to GlaxoSmithKline.

2017

Hagberg KW, Divan HA, Fang SC, Nickel JC, Jick SS. Risk of gynecomastia and breast cancer associated with the use of 5-alpha reductase inhibitors for benign prostatic hyperplasia. Clin Epidemiol. 2017. doi:10.2147/CLEP.S124674 • PubMed

Hagberg KW, Divan HA, Nickel JC, Jick SS. Risk of incident antidepressant-treated depression associated with use of 5α-reductase inhibitors compared with use of α-blockers in men with benign prostatic hyperplasia: a population-based study using the Clinical Practice Research Datalink. Pharmacotherapy. 2017. doi:10.1002/phar.1925 • PubMed

2016

Hagberg KW, Divan HA, Persson R, Nickel JC, Jick SS. Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. BMJ. 2016. doi:10.1136/bmj.i4823 • PubMed

2012

Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, Black L, Rittmaster RS. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012. doi:10.1016/S0140-6736(11)61619-X • PubMed

2011

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS [GSK]. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011. doi:10.1111/j.1464-410X.2011.10195.x • PubMed

2010

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS [GSK], for the REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010. doi:10.1056/NEJMoa0908127 • PubMed

2007

Fleshner N, Gomella LG, Cookson MS, Finelli A, Evans A, Taneja SS, Lucia MS, Wolford E, Somerville MC, Rittmaster R, for the REDEEM Study Group. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007. doi:10.1016/j.cct.2007.05.006 • PubMed

2004

Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Lazier CB, Rittmaster RS. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004. doi:10.1097/01.ju.0000136430.37245.b9 • PubMed

Roehrborn CG, Bruskewitz R, Nickel JCMcConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, for the Proscar Long-Term Efficacy and Safety Study Group. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol. 2004. doi:10.1097/01.ju.0000112918.74410.94 • PubMed

2003

Lowe FC, McConnell JD, Hudson PB, Romas NA, Boake R, Lieber M, Elhilali M, Geller J, Imperato-McGinley JAndriole GL, Bruskewitz RC, Walsh PC, Bartsch G, Nacey JN, Shah S, Pappas F, Ko A, Cook T, Stoner EWaldstreicher J, for the Finasteride Study Group. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 2003. doi:10.1016/s0090-4295(02)02548-7 • PubMed

McConnell JDRoehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor HMcVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003. doi:10.1056/NEJMoa030656 • PubMed

Pearson JD, Lei HH, Beaty TH, Wiley KE, Isaacs SD, Isaacs WB, Stoner EWalsh PC. Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology. 2003. doi:10.1016/s0090-4295(02)02509-8 • PubMed

Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, Herlihy R, Fitch W, Labasky R, Auerbach S, Parra R, Rajfer J, Culbertson J, Lee M, Bach MA, Waldstreicher J, for the PLESS Study Group. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology. 2003. doi:10.1016/s0090-4295(02)02401-9 • PubMed

2002

Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. World J Urol. 2002. doi:10.1007/s00345-002-0248-5 • PubMed

Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, for ARIA Study Investigators. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002. doi:10.1016/s0090-4295(02)01905-2 • PubMed

Vaughan D, Imperato-McGinley JMcConnell J, Matsumoto AM, Bracken B, Roy J, Sullivan M, Pappas F, Cook T, Daurio C, Meehan A, Stoner EWaldstreicher J. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology. 2002. doi:10.1016/s0090-4295(02)01971-4 • PubMed

2000

Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother. 1995. doi:10.1016/0753-3322(96)82658-8

Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F, Waldstreicher J, for the PLESS Study Group. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology. 2000. doi:10.1016/s0090-4295(00)00724-x • PubMed

Marberger MJ, Andersen JT, Nickel JC, Malice MP, Gabriel M, Pappas F, Meehan A, Stoner EWaldstreicher J. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Combined experience from three large multinational placebo-controlled trials. Eur Urol. 2000. doi:10.1159/000020356 • PubMed

Roehrborn CG, Bruskewitz R, Nickel JC, Glickman S, Cox C, Anderson R, Kandzari S, Herlihy R, Kornitzer G, Brown BT, Holtgrewe HL, Taylor A, Wang D, Waldstreicher J, for the PLESS Study Group. Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. Eur Urol. 2000. doi:10.1159/000020189 • PubMed

1999

Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J, for the PLESS Study Group. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. Proscar Long-term Efficacy and Safety Study. Urology. 1999. doi:10.1016/s0090-4295(99)00209-5 • PubMed

Roehrborn CGMcConnell JD, Lieber M, Kaplan S, Geller J, Malek GH, Castellanos R, Coffield S, Saltzman B, Resnick M, Cook TJ, Waldstreicher J, for the PLESS Study Group. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. Urology. 1999. doi:10.1016/s0090-4295(98)00654-2 • PubMed

Yang XJ, Lecksell K, Short K, Gottesman J, Peterson L, Bannow J, Schellhammer PF, Fitch WP, Hodge GB, Parra R, Rouse S, Waldstreicher J, Epstein JI. Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology. 1999 Apr. doi:10.1016/s0090-4295(98)00579-2 • PubMed

1998

Andriole GL, Guess HA, Epstein JI, Wise H, Kadmon D, Crawford ED, Hudson P, Jackson CL, Romas NA, Patterson L, Cook TJ, Waldstreicher J, for the PLESS Study Group. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. Urology. 1998. doi:10.1016/s0090-4295(98)00184-8 • PubMed

McConnell JD, Bruskewitz R, Walsh PAndriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CGNickel JC, Wang DZ, Taylor AM, Waldstreicher J, for the Finasteride Long-Term Efficacy and Safety Study Group. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med. 1998. doi:10.1056/NEJM199802263380901 • PubMed

Lepor H, Williford WO, Barry MJ, Haakenson C, Jones K, for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. J Urol. 1998. PubMed

1997

Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, Stoner EWalsh PC. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol. 1997. doi:10.1016/S0022-5347(01)65069-9 • PubMed

1996

Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ, for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N Engl J Med. 1996. doi:10.1056/NEJM199608223350801 • PubMed

Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, Elhilali MM, and the PROSPECT Study Group. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). CMAJ. 1996. PubMed • PMC full text

1995

Gormley GJ. Finasteride: a clinical review. Biomed Pharmacother. 1995. doi:10.1016/0753-3322(96)82658-8

Kaplan S, Garvin D, Gilhooly P, Koppel M, Labasky R, Milsten R, Reddy P, Rosenberg S, Sussman D, White C, Lee M, Pappas F, Waldstreicher J, for the PLESS Study Group. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. Urology. 2000. doi:10.1016/s0090-4295(00)00724-x • PubMed

1992

Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T, Lundmo P, Pappas F, Round E, Shapiro D, Stoner E, Swartz R, Varenhorst E, for the Scandinavian Clinical Study of Finasteride in the Treatment of Benign Prostatic Hyperplasia. European Urology. 1992. doi:10.1159/000474771 • PubMed

Gormley GJStoner E, Bruskewitz RC, Imperato-Mcginley JWalsh PCMcConnell JDAndriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 1992. doi:10.1056/NEJM199210223271701 • PubMed

Gormley GJStoner E, Bruskewitz RC, Imperato-McGinley JWalsh PCMcConnell JDAndriole GL, Geller J, Bracken BR, Tenover JS, Vaughan ED, Pappas F, Taylor A, Binkowitz B, Ng J, for the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. 1992. J Urol. 2002. doi:10.1016/s0022-5347(02)80349-4 • PubMed

McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992. doi:10.1210/jcem.74.3.1371291 • PubMed

1991

De Schepper PJ, Imperato-McGinley J, Van Hecken A, De Lepeleire I, Buntinx A, Carlin J, Gressi MH, Stoner E. Hormonal effects, tolerability, and preliminary kinetics in men of MK-906, a 5 alpha-reductase inhibitor. Steroids. 1991. doi:10.1016/0039-128x(91)90003-e • PubMed

[Gormley GJ] The MK-906 (Finasteride) Study Group. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. J Androl. 1991. doi:10.1002/j.1939-4640.1991.tb00277.x • PubMed

1990

Gormley GJStoner ERittmaster RS, Gregg H, Thompson DL, Lasseter KC, Vlasses PH, Stein EA. Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers. J Clin Endocrinol Metab. 1990. doi:10.1210/jcem-70-4-1136 • PubMed

Imperato-McGinley J, Shackleton C, Orlic S, Stoner E. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. J Clin Endocrinol Metab. 1990. doi:10.1210/jcem-70-3-777 • PubMed

1989

Rittmaster RSStoner E, Thompson DL, Nance D, Lasseter KC. Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men. J Androl. 1989. doi:10.1002/j.1939-4640.1989.tb00097.x • PubMed

1987

Rittmaster RS, Uno H, Povar ML, Mellin TN, Loriaux DL. The effects of N,N-diethyl-4-methyl-3-oxo-4-aza-5 alpha-androstane-17 beta-carboxamide, a 5 alpha-reductase inhibitor and antiandrogen, on the development of baldness in the stumptail macaque. J Clin Endocrinol Metab. 1987. doi:10.1210/jcem-65-1-188 • PubMed